TIGIT Immunotherapy Market Advances With Growing Focus on Immune...

toegevoegd een audio Health

2026-09-08 14:41:01 -

TIGIT Immunotherapy Market Advances With Growing Focus on Immune Checkpoint Targets

Cancer immunotherapy has a new name generating buzz beyond PD-1 and PD-L1: TIGIT, short for T-cell immunoreceptor with Ig and ITIM domains. Sitting on the surface of activated T cells, natural killer cells, and regulatory T cells, TIGIT locks onto the ligands CD155 and CD112, which tumors use to keep the immune system quiet. Block that handshake, and CD226 signaling on NK and CD8+ T cells...

0 Reacties 0 aandelen 977 Views 0 voorbeeld